Stock of Repare Therapeutics Inc. (RPTX) performance and profitability takes another direction

Repare Therapeutics Inc. [RPTX] stock prices are up up 5.04% to $13.13 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RPTX shares have gain 3.55% over the last week, with a monthly amount drifted -12.70%, and not seem to be holding up well over a long-time horizon.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


On 4, August 2022, Repare Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results. In a post published today on Yahoo Finance, Signed worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (also known as RP-3500).

From an analyst’s perspective:

Repare Therapeutics Inc. [NASDAQ: RPTX] stock has seen the most recent analyst activity on April 12, 2022, when Stifel downgraded its rating to a Hold but kept the price target unchanged to $11 for it. On September 23, 2021, Stifel initiated with a Buy rating and assigned a price target of $48 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $54 on September 13, 2021. Guggenheim initiated its recommendation with a Buy and recommended $46 as its price target on June 28, 2021. Berenberg started tracking with a Buy rating for this stock on March 01, 2021, and assigned it a price target of $51. In a note dated October 28, 2020, Northland Capital initiated an Outperform rating and iterated a target price of $38 on this stock.

The stock price of Repare Therapeutics Inc. [RPTX] has been fluctuating between $8.06 and $35.75 over the past year. Currently, Wall Street analysts expect the stock to reach $31.25 within the next 12 months. Repare Therapeutics Inc. [NASDAQ: RPTX] shares were valued at $13.13 at the most recent close of the market. An investor can expect a potential return of 138.0% based on the average price forecast.

Analyzing the RPTX fundamentals

The most recent quarter, Repare Therapeutics Inc. [NASDAQ:RPTX] reported sales of 408.0 million, representing a surge of 100.00%. Gross Margin for this corporation currently stands at +56.00% with Operating Margin at -1414.95%, Pretax Margin comes in at -1413.97%, and Net Margin reading is -1406.68%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.75 points at the first support level, and at 12.36 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.39, and for the 2nd resistance point, it is at 13.64.

Repare Therapeutics Inc. [RPTX] reported earnings per share of -$0.83 for its fiscal quarter that ended on 3/30/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.86/share, meaning a difference of $0.03 and a surprise factor of 3.50%. By comparison, the stated earnings for the previous quarter ended on 12/30/2021 were -$0.7 per share as compared to estimates of -$0.74 per share, a difference of $0.04 representing a surprise of 5.40%.

Ratios To Look Out For

It’s worth pointing out that Repare Therapeutics Inc. [NASDAQ:RPTX]’s Current Ratio is 9.40. In addition, the Quick Ratio stands at 10.01 and the Cash Ratio stands at 9.74. Considering the valuation of this stock, the price to sales ratio is 104.95, the price to book ratio is 3.06.

Transactions by insiders

Recent insider trading involved BVF PARTNERS L P/IL, 10% Owner, that happened on Jun 13 when 0.15 million shares were purchased. 10% Owner, BVF PARTNERS L P/IL completed a deal on Jun 06 to buy 6869.0 shares. Meanwhile, 10% Owner BVF PARTNERS L P/IL bought 0.64 million shares on Jun 03.